Trevi Therapeutics, Inc. (TRVI) stock
TRVINasdaqPharmaceutical PreparationsFiscal year ends December 31
$13.72+0.21 (+1.55%)
Close on Nov 19, 2026Market cap $1.95BP/E –Yield –
Trevi Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Trevi Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$52.87M. For fiscal 2025 it was -$42.10M. The highest annual figure on record is -$18.45M in fiscal 2018.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$42.10M | – |
| FY2024 | Dec 31, 2024 | -$38.29M | – |
| FY2023 | Dec 31, 2023 | -$31.85M | – |
| FY2022 | Dec 31, 2022 | -$28.33M | – |
| FY2020 | Dec 31, 2020 | -$29.03M | – |
| FY2019 | Dec 31, 2019 | -$23.10M | – |
| FY2018 | Dec 31, 2018 | -$18.45M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$17.55M | – |
| Q1 FY2026 | Mar 31, 2026 | -$16.79M | – |
| Q4 FY2025 | Dec 31, 2025 | -$7.63M | – |
| Q3 FY2025 | Sep 30, 2025 | -$10.89M | – |
| Q4 FY2024 | Dec 31, 2024 | -$9.56M | – |
| Q3 FY2024 | Sep 30, 2024 | -$9.56M | – |
| Q4 FY2023 | Dec 31, 2023 | -$6.38M | – |
| Q3 FY2023 | Sep 30, 2023 | -$7.30M | – |
| Q2 FY2023 | Jun 30, 2023 | -$9.92M | – |
| Q1 FY2023 | Mar 31, 2023 | -$8.25M | – |
| Q4 FY2022 | Dec 31, 2022 | -$6.45M | – |
| Q4 FY2020 | Dec 31, 2020 | -$8.93M | – |
| Q3 FY2020 | Sep 30, 2020 | -$6.98M | – |
| Q4 FY2019 | Dec 31, 2019 | -$6.20M | – |
| Q3 FY2019 | Sep 30, 2019 | -$7.73M | – |
| Q2 FY2019 | Jun 30, 2019 | -$5.06M | – |
| Q1 FY2019 | Mar 31, 2019 | -$4.11M | – |
| Q4 FY2018 | Dec 31, 2018 | -$4.82M | – |
| Q3 FY2018 | Sep 30, 2018 | -$3.99M | – |
| Q2 FY2018 | Jun 30, 2018 | -$5.62M | – |
| Q1 FY2018 | Mar 31, 2018 | -$4.01M | – |
See a number that looks wrong?